BofA raised the firm’s price target on Emerson (EMR) to $155 from $130 and keeps a Buy rating on the shares. The firm’s summit with distributors provided no big surprises, with the firm telling investors in a research note that short-cycle data points are not “great,” but not worse, and in some areas sound solid. BofA argues that a discount is warranted given by higher financial leverage and merger integration risks.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: